Yes they did. John Doukas was due to present at the Emerging Immunotherapy conference on 14th-15th August. He was chairing the afternoon meetings. It could be to do with the fact that they've got major data coming out and they don't want it leaked, what with class action and stock manipulation all over biotech like a rash. Anyway, have you read the highly informative tweet by K.Rudolph on the VICL market stream? It's a link to an academic article summarising past Allovectin 7 trials.